# Methylphenidate

## Concerta ER 27mg

| TAH Drug Code      | [OCON2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCON2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For treatment of attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Attention deficit disorder : (Child over 6 years and adult) Concerta: 27mg(1 TAB) QD. ( maximum for Child: 54 mg/day; maximum for adult : 72 mg/day )                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Patients with marked anxiety, tension & agitation, glaucoma, Tourette's syndrome, & patients on MAOI therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Headache, stomach ache, loss of appetite, insomnia, aggravation reaction, asthenia, hypertension, nausea &/or vomiting, dyspepsia, weight loss, twitching (tics), dizziness, emotional lability, somnolence, anxiety, depression, nervousness, hostility, rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% ), Loss of appetite (5% ), Nausea (12% ), Vomiting (10% ) Neurologic: Headache, Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% ), Nasopharyngitis (5% ) |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## CONCERTA 36mg

| TAH Drug Code      | [OCON3](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCON3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For treatment of attention deficit hyperactivity disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Attention deficit disorder : (Child over 6 yrs and adult) Concerta: 36mg(1 TAB) QD. (maximum for Child: 54 mg/day; maximum for adult : 72 mg/day )                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Patients with marked anxiety, tension & agitation, glaucoma, Tourette's syndrome, & patients on MAOI therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Headache, stomach ache, loss of appetite, insomnia, aggravation reaction, asthenia, hypertension, nausea &/or vomiting, dyspepsia, weight loss, twitching (tics), dizziness, emotional lability, somnolence, anxiety, depression, nervousness, hostility, rash. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% ), Loss of appetite (5% ), Nausea (12% ), Vomiting (10% ) Neurologic: Headache, Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% ), Nasopharyngitis (5% ) |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## apo-Methylphenidate 10mg

| TAH Drug Code      | [OMET1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMET1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Attention-deficit hyperactivity disorder; narcolepsy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | Children >= 6 years: Initially 5 mg QD or BID with gradual increments of 5-10 mg weekly. maximum: 60 mg/day.Adult: 10 to 60 mg/day divided 2 to 3 times, preferably 30 to 45 minutes before meals. If the patient is unable to fall asleep due to taking the medicine late, the last dose should be taken before 6 pm. If no improvement in symptoms is seen after an appropriate dose adjustment for more than one month, the drug should be discontinued.                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Anxiety & tension states, agitation, tics, tics in siblings, family history or diagnosis of Tourette's syndrome; glaucoma; hyperthyroidism; cardiac arrhythmias, severe angina pectoris.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Frequent: nervousness, insomnia, decreased appetite. Occasional: headache, drowsiness, dizziness, dry mouth, tachycardia, palpitations, arrhythmias, changes in BP & heart rate; GI disturbances, skin reactions, fever, arthralgia. Rare: blurred vision, moderately reduced weight gain & minor growth retardation in children. Dermatologic: Erythema Endocrine metabolic: Weight decreased (9% ) Gastrointestinal: Decrease in appetite (26% ), Loss of appetite (5% ), Nausea (12% ), Vomiting (10% ) Neurologic: Headache, Insomnia (13% ) Psychiatric: Labile affect (6% ) Respiratory: Nasal congestion (6% ), Nasopharyngitis (5%) |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

## Methydur 22mg sustained release

| TAH Drug Code      | [OMTD22](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OMTD22)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment for Attention Deficit Hyperactivity Disorder (ADHD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Dosing             | Take once daily, within 20 minutes after breakfast, with water. Do not chew, split, or crush the capsules. For patients not previously taking Methylphenidate or other stimulants: 22mg/day. If the desired effect is not achieved: increase dose by 11mg every 7 days (max 44mg/day).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to methylphenidate or other components of the product, Marked agitation, anxiety, and tension; may aggravate symptoms, Glaucoma, Motor tics, Concomitant use of MAOIs, or use within 14 days of MAOI discontinuation, Family history or diagnosis of Tourette syndrome, Fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency; contains sucrose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Common: Tachycardia (4.8-7%), Diaphoresis (Adult, 5.1%), Weight decreased (2.4-12%), Abdominal pain (Pediatric 4-15%), Decrease in appetite (2-35%), Loss of appetite (Adult 1.7% ; pediatric 3.1-9% or greater ), Nausea (2.4-12.8%), Vomiting (1.7-9%), Xerostomia (3-14%), Dizziness (Adult 6.7%; pediatric 1.9-3%), Headache (Adult 22.2% ; pediatric 2.4-19%), Insomnia (2.8-41%), Anxiety (Adult 8.2%), Depression (Adult 1.7-3.9%), Irritability (5.8-10%) Serious: Myocardial infarction, Raynaud's phenomenon, Sudden cardiac death, Decreased body growth, Gastrointestinal obstruction, With preexisting severe gastrointestinal narrowing and use of controlled-release formulations, Abnormal liver function, Cerebral artery occlusion, Cerebral hemorrhage, Cerebrovascular accident, Lowered convulsive threshold, Seizure, Blurred vision (>1.7-2%), Aggressive behavior (1.7-2.4%), Mania, Psychotic disorder, Priapism, Drug abuse, Substance dependence |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

